Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: The AREA-in-CHF study

G. De Simone, M. Chinali, G. F. Mureddu, G. Cacciatore, D. Lucci, R. Latini, S. Masson, M. Vanasia, A. P. Maggioni, A. Boccanelli

Research output: Contribution to journalArticle

Abstract

Background and aim: We analyzed the effect of the mineralocorticoid receptor antagonist canrenone on LV mechanics in patients with or without metabolic syndrome (MetS) and compensated (Class II NYHA) heart failure (HF) with reduced ejection fraction (EF ≤ 45%) on optimal therapy (including ACE-i or ARB, and β-blockers). Methods and results: From a randomized, double-blind placebo-controlled trial (AREA-in-CHF), patients with (73 on canrenone [Can] and 77 on placebo [Pla]), based on modified ATPIII definition (BMI≥30kg/m2 instead of waist girth) or without MetS (146 by arm). In addition to traditional echocardiographic parameters, we also evaluated myocardial mechano-energetic efficiency (MME) based on a previously reported method. At baseline, Can and Pla did not differ in age, BMI, blood pressure (BP), metabolic profile, BNP, and PIIINP. Compared with MetS-Pla, and controlling for age, sex and diabetes, at the final control MetS-Can exhibited increased MME, preserved E/A ratio, and decreased atrial dimensions (0.04

Original languageEnglish
Pages (from-to)783-791
Number of pages9
JournalNutrition, Metabolism and Cardiovascular Diseases
Volume21
Issue number10
DOIs
Publication statusPublished - Oct 2011

    Fingerprint

Keywords

  • Atrial dilatation
  • Brain natriuretic peptide
  • Diastolic dysfunction
  • Ejection fraction
  • Procollagen type III amino-terminal peptide
  • Systolic dysfunction

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this